Humoral Immune Response to Messenger RNA COVID-19 Vaccines Among Patients With Inflammatory Bowel Disease.

"Conflicts of interest These authors disclose the following: Michael D. Kappelman has consulted for 10.13039/100006483Abbvie , Janssen, 10.13039/100004319Pfizer , and Takeda; is a shareholder in Johnson & Johnson; and has received research support from 10.13039/100004319Pfizer , Takeda, Janssen, 10.13039/100006483Abbvie , 10.13039/100004312Lilly , Genentech, Boehringer Ingelheim, 10.13039/100008021Bristol Myers Squibb , Celtrion, and Arenapharm. Millie Long has received research/grants from 10.13039/100004319Pfizer Inc and has consulted for 10.13039/100006483AbbVie Inc, Bristol-Myers Squibb Company, Calibr, 10.13039/100004312Eli Lilly and Company , Genentech, Inc, 10.13039/100005564Gilead Sciences , Inc, 10.13039/100008897Janssen Pharmaceuticals , Inc, 10.13039/100004319Pfizer Inc, 10.13039/100004337Roche , 10.13039/100007723Takeda Pharmaceuticals U.S.A. , Inc, TARGET PharmaSolutions, Inc, and Theravance Biopharma. These authors from the PREVENT-COVID Study Group disclose the following: JA has consulted for Janssen and has received research support from The Gary and Rachel Glick Charitable Fund, Shaevsky Family Research Fund for Crohn's Disease, the Crohn’s & Colitis Foundation, and The Leona M. and Harry B. Helmsley Charitable Trust. MCD has received consultant fees from 10.13039/100006483Abbvie , Arena, 10.13039/100008021Bristol Myers Squibb , Celgene, Gilead, Janssen, 10.13039/100004319Pfizer , Prometheus Labs, and Takeda; grant support from 10.13039/100006483Abbvie and 10.13039/100008953Prometheus Labs; and license fees from Takeda. AB has been a subinvestigator on trials for Prometheus, Janssen, Abbvie, Takeda, Buhlmann, Arena, and Eli Lilly in the past 36 months and has consulted for Arena, Tekeda, Best Doctors, and Eli Lilly. JAS has consulted for Janssen and has received research support from The Gary and Rachel Glick Charitable Fund, Shaevsky Family Research Fund for Crohn's Disease, the Crohn’s & Colitis Foundation, and The Leona M. and Harry B. Helmsley Charitable Trust. RKC has participated in advisory boards and has consulted for Abbvie, Bristol Myers Squibb, Janssen, LabCorp, Pfizer, Samsung Bioepis, and Takeda. PDRH has consulted for 10.13039/100006483Abbvie , 10.13039/100004319Pfizer , and Takeda and has received grant support from the 10.13039/100000002National Institutes of Health , CCF, 10.13039/100006483Abbvie , 10.13039/100004319Pfizer , Takeda, Genentech, Eli 10.13039/100004312Lilly , Arena, and the Rainin Foundation. RCU has served as an advisory board member or consultant for 10.13039/100006483AbbVie , 10.13039/100008021Bristol Myers Squibb , Eli 10.13039/100004312Lilly , Janssen, 10.13039/100004319Pfizer , and Takeda and has received research support from 10.13039/100006483AbbVie , Boehringer Ingelheim, and 10.13039/100004319Pfizer . RCU is funded by a 10.13039/100000002National Institutes of Health Career Development Award (K23KD111995-01A1). MB discloses research funding from Janssen, 10.13039/100004330GlaxoSmithKline , and Takeda; has served as a consultant for Janssen, 10.13039/100006483AbbVie , BMS, and Pfizer; and has received honorarium for participation in a CME program sponsored by 10.13039/100006483AbbVie . EB has consulted for Abbvie, Pfizer, and Bristol Myers Squibb. FAF is a consultant for Arena, BMS, Braintree Labs, Gilead, GI Reviewers, Innovation Pharmaceuticals, Iterative Scopes, Janssen, Pfizer, and Sebela and sits on a Data Safety Monitoring Board for Lilly and Theravance. The remaining authors disclose no conflicts."

"Funding This research was funded by the 10.13039/100007028Helmsley Charitable Trust ."